--Rigel Pharmaceuticals, Inc. today announced a collaboration with CONNECT, an international collaborative network of pediatric cancer centers, to conduct a Phase 2 clinical trial to evaluate ...

Rigel Pharmaceuticals Annual EPS Estimates (Seeking Alpha) As for the annual EPS, we can see that the Street has Rigel’s earnings rising through 2030, going from -0.38 for 2024 to 2.18 for 2030.

Rigel Pharmaceuticals Q1 Highlights (Rigel Pharmaceuticals) Perhaps the most impressive item to highlight is that TAVALISSE brought home $28.5M in Q1, which was a 35% year-over-year increase.

Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Rigel, Aurous, and the Target Companies and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced upcoming presentations from their commercial and clinical-stage hematology and oncology portfolio at the 2024 American Society of ...

Rigel's stock has plunged 52.2% over the past three months through Thursday, while the iShares Biotechnology ETF has rallied 13.2% and the S&P 500 has gained 3.9%. Show Conversation (0) ...